Search

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

EHA Kick-off Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

ESID-EHA-SIOPE Focused Symposium 2025

Explore the interplay of immunodeficiency, hematologic conditions, and pediatric cancer at a unique, collaborative symposium. Dates: November 18–20, 2025
Location: Vienna, Austria

Abstract submission is open until 23:59 (CEST) on June 10, 2025.

Read more

Compliance and reports

EHA is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.

Read more

Mesenchymal Stromal Cells (MSC)

The focus of the current MSC Specialized Working Group is to better understand mechanisms through which MSCs could modulate immune responses, identify individual cells belonging to the innate and adaptive immune responses that interact with MSCs and define the molecular…

Read more